Ruxolitinib therapy for myelofibrosis in Austria

Maria‐Theresa Krauth(Medical University of Vienna), Heinz Gisslinger(Medical University of Vienna), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Peter Krippl, Holger Rumpold(Innsbruck Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Albert Wölfler(Medical University of Graz), Stefan Wöhrer(Fachhochschule Wiener Neustadt), Klaus Geißler(University of Vienna), Thomas Melchardt(Paracelsus Medical University), Felix Keil(Hanusch Hospital), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Günther Gastl(Innsbruck Medical University), Thamer Sliwa(Hanusch Hospital)
Wiener klinische Wochenschrift
July 24, 2018
10.1007/s00508-018-1365-5
Cited by 6

Related Papers

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
|Blood|2012|596
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448